Evaluating the effects of 5‐aminosalicylic acid on tofacitinib treatment in ulcerative colitis
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Yu Nishida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Mesalamine, Piperidines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background and Aim Tofacitinib and aminosalicylic acid (5‐ASA) are commonly used to treat ulcerative colitis (UC). However, evidence on the effect of concomitant 5‐ASA use in patients receiving tofacitinib is limited. This study investigated the effects of 5‐ASA combined with tofacitinib in UC patients.
Methods
This retrospective cohort study used data from the Medical Data Vision database, including patients with UC treated with tofacitinib from May 2018 to April 2022. Patients were grouped according to tofacitinib dosage and assessed for the efficacy of concomitant 5‐ASA use. The primary endpoint was clinical relapse.
Results
A total of 1213 patients with UC were included in the analysis, with 416 in the 5 mg BID group and 797 in the 10 mg BID group. In the 5 mg BID group, the cumulative relapse‐free rate was significantly higher in patients receiving concomitant 5‐ASA ( P < 0.0001). Multivariate Cox regression analysis confirmed that concomitant 5‐ASA use significantly reduced the risk of clinical relapse (adjusted hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.31–0.70). In the 10 mg BID group, no significant difference was noted in the cumulative relapse‐free rate between patients treated with and without 5‐ASA ( P = 0.445). Similarly, multivariate Cox regression analysis indicated that concomitant 5‐ASA use did not significantly affect relapse risk (adjusted HR, 0.97; 95% CI, 0.71–1.32).
Conclusions
Concomitant 5‐ASA use reduced the risk of relapse in patients on 5 mg tofacitinib BID, suggesting benefits at lower doses. However, no significant benefit was observed with 5‐ASA use in those 10 mg tofacitinib BID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
ORCID-Profile: Yu Nishida, Shuhei Hosomi, Koji Fujimoto, Koji Otani
Zitieren
APA
Nishida, Y., Hosomi, S., Fujimoto, K., Kobayashi, Y., Nakata, R., Maruyama, H., Ominami, M., Nadatani, Y., Fukunaga, S., Otani, K., Tanaka, F., & Fujiwara, Y. (2025). Evaluating the effects of 5‐aminosalicylic acid on tofacitinib treatment in ulcerative colitis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16786
Vancouver
Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, et al. Evaluating the effects of 5‐aminosalicylic acid on tofacitinib treatment in ulcerative colitis. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16786
BibTeX
@article{Nishida2025,
author = {Nishida, Yu and Hosomi, Shuhei and Fujimoto, Koji and Kobayashi, Yumie and Nakata, Rieko and Maruyama, Hirotsugu and Ominami, Masaki and Nadatani, Yuji and Fukunaga, Shusei and Otani, Koji and Tanaka, Fumio and Fujiwara, Yasuhiro},
title = {Evaluating the effects of 5‐aminosalicylic acid on tofacitinib treatment in ulcerative colitis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16786}
}
EUVIMED